Cell Therapy Treatments for COVID-19
Thursday, May 21, 2020 at 11 AM EST
This webinar will highlight potential treatments for Acute Respiratory Distress syndrome (ARDS) in COVID-19 patients. Two therapeutic developers, Athersys and Pluristem Therapeutics, will present on their treatment approaches and plans for near term clinical trials.
Speakers:
Eric Jenkins, M.D., Senior Medical Director and Head of Clinical Operations, Athersys
Dr. Jenkins rejoined Athersys as Medical Director in 2016, where he is responsible for medical oversight of all clinical development activities. With 20 years of clinical experience, he contributes medical expertise to the Company’s long-term strategic planning and serves as the medically-informed voice for external communications with clinical investigators, regulators, key opinion-leaders and patient communities. In addition, Dr. Jenkins currently leads the pure-commercial medical affairs activities, including preparation for market access, coding and reimbursement for MultiSteam cell therapy products following approval.
Racheli Ofir, Ph.D., Vice President Research and Intellectual Property, Pluristem Therapeutics
Dr. Ofir joined Pluristem in 2007, as Vice President of research and intellectual property. The Research Department examines the various cells developed by the company, the properties of those cells and their mechanisms of action by using molecular methods and animal models to test the safety and efficacy. The IP department is responsible for intellectual property strategy development as well as the research that supports the IP. Dr. Ofir is responsible for leading projects involving the characterization of PLX cells, Pluristem’s leading placenta derived cell product candidate, including evaluating the biological activity of the cells in in-vitro and animal studies. She is responsible for the studies which determines the safety profile and pharmacokinetics of PLX cells.
RSVP to listen the free webinar here.